This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ireland Welcomes Watson Pharmaceuticals, an American Success

NEW YORK ( TheStreet) -- Watson Pharmaceuticals, founded by a Taiwanese immigrant in the early 1980s and now a rival to generic drug giants Teva Pharmaceuticals (TEVA - Get Report) and Novartis (NVS - Get Report), is such an American success story the company has wound up in Ireland.

On Monday, Watson capped its intercontinental move when the company announced a $8.5 billion deal to buy Dublin-based- Warner Chilcott (WCRX). In order to take advantage of byzantine tax and merger laws, the combined company will now incorporate in Ireland, ending Watson's spectacular three-decade rise to become a U.S. success story in the global pharmaceutical market.

Watson was founded in 1985 by an immigrant Purdue University Ph.D., Allen Chao, and a colleague, David S. Hsia, as a fledgling pharmaceutical with a few million dollars raised by friends and family in the Taiwanese community living in California.

The company's growth to a market cap of over $16 billion and the third leading share of the generics market is nearly on par with the rise of Intel (INTC), Google (GOOG), and Yahoo! (YHOO - Get Report), all great American businesses founded in the U.S. by first generation immigrants.

Its move abroad, however, underscores that while the U.S. remains a hotbed of innovation, successful companies are using tax loopholes to leave the country's shores.

In the case of Watson Pharmaceuticals, the corporate shape-shifting it has undertaken in the name of tax avoidance is likely to obscure the company's enterprising immigrant roots.

Already, much of Watson Pharmaceuticals' history has been bleached over by corporate PR to effectuate its move to Ireland.

In 2012, Watson Pharmaceuticals acquired Actavis, a Swiss competitor in the generic drugs market. While Watson was the acquirer, the company nevertheless changed its name to Actavis.

"A pioneer at the dawn of the U.S. generic industry in 1984, the Watson corporate name was never registered globally... it became clear that we could not establish a single, unified market presence under the Watson brand," CEO Paul Bisaro said in an October 2012 statement.

[Watson Pharmaceuticals name was an amalgamation of founder Allen Chao's Taiwanese mother's maiden name 'Hwa' and 'son.' The company mostly makes generic drugs.]

Watson also changed its ticker on the New York Stock Exchange from 'WPI' to 'ACT' in 2013 and hence Actavis, a U.S.-European conglomerate, was born.

In that deal, Actavis represented only about 30% of the combined company's revenue, according to internal projections.

On Actavis's web site, little remains of the roots of the parent company, Watson Pharmaceuticals, or its fantastic rags-to-riches-story.

For instance, there is no 'history' section to detail Watson's growth from Purdue University to the heights of the pharmaceuticals market. A 1994 Forbes Magazine profile, Still Running Scared, is likely to be end up the best reminder of Watson's accomplishments.

Wiping Watson Pharmaceuticals from the history books may be a matter of convenience in moving the parent company from New Jersey to Ireland for tax reasons. It may also have PR benefits, if anonymity is what the pharmaceutical company's top management wants. It's much easier for the media to turn a blind eye to Actavis, a company with Swiss roots incorporating in Ireland, than Watson, with its proud entrepreneurial history in the U.S.

Follow the money, however, and it's clear that on Monday it was Watson Pharmaceuticals that incorporated in Ireland ostensibly to dodge US taxes.

While Watson's legacy businesses have lost their name and their home, they will nevertheless represent about 50% of "New Actavis's" overall pro-forma revenue.

In one acquisition, Watson picked up a new name and in the other, it found a new home.

According to Monday's all-stock merger, Warner Chilcott shareholders will receive 0.160 shares of "New Actavis" for each Warner Chilcott share they own, equating to a $20.08 per share value according to May 17 closing prices.

"New Actavis," in this instance, doesn't just mean the merged company. It also signifies the firm's new Irish incorporation.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WCRX $0.00 0.00%
ACT $0.00 0.00%
NVS $74.12 0.00%
TEVA $53.87 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs